La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Instem Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Phil Reason

Amministratore delegato

UK£300.0k

Compenso totale

Percentuale dello stipendio del CEO	78.7%
Mandato del CEO	no data
Proprietà del CEO	3.2%
Durata media del management	4.8yrs
Durata media del Consiglio di amministrazione	1.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

Is Instem plc's (LON:INS) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Mar 03

Shareholders Are Thrilled That The Instem (LON:INS) Share Price Increased 190%

Jan 29

Calculating The Intrinsic Value Of Instem plc (LON:INS)

Dec 25

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Phil Reason rispetto agli utili di Instem?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2023	n/a	n/a	UK£3m
Mar 31 2023	n/a	n/a	UK£4m
Dec 31 2022	UK£300k	UK£236k	UK£5m
Sep 30 2022	n/a	n/a	UK£3m
Jun 30 2022	n/a	n/a	UK£2m
Mar 31 2022	n/a	n/a	UK£2m
Dec 31 2021	UK£279k	UK£204k	UK£2m
Sep 30 2021	n/a	n/a	UK£2m
Jun 30 2021	n/a	n/a	UK£2m
Mar 31 2021	n/a	n/a	UK£2m
Dec 31 2020	UK£276k	UK£226k	UK£2m
Sep 30 2020	n/a	n/a	UK£1m
Jun 30 2020	n/a	n/a	UK£339k
Mar 31 2020	n/a	n/a	-UK£292k
Dec 31 2019	UK£261k	UK£223k	-UK£923k
Sep 30 2019	n/a	n/a	UK£418k
Jun 30 2019	n/a	n/a	UK£2m
Mar 31 2019	n/a	n/a	UK£2m
Dec 31 2018	UK£243k	UK£207k	UK£1m
Sep 30 2018	n/a	n/a	UK£1m
Jun 30 2018	n/a	n/a	UK£1m
Mar 31 2018	n/a	n/a	UK£1m
Dec 31 2017	UK£246k	UK£210k	UK£642k
Sep 30 2017	n/a	n/a	UK£470k
Jun 30 2017	n/a	n/a	UK£297k
Mar 31 2017	n/a	n/a	UK£678k
Dec 31 2016	UK£241k	UK£194k	UK£1m

Compensazione vs Mercato: La retribuzione totale di Phil ($USD 375.21K ) è inferiore alla media delle aziende di dimensioni simili nel mercato UK ($USD 751.95K ).

Compensazione vs guadagni: La retribuzione di Phil è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Phil Reason (61 yo)

no data

Mandato

UK£300,000

Compensazione

Mr. Phil J. Reason serves as the Chief Executive Officer of Instem LSS Limited, Instem Associates Limited and Instem plc (Instem Life Science Systems plc). Mr. Reason is an experienced chief executive who...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Phil Reason	CEO & Executive Director	no data	UK£300.00k	3.2% £ 6.4m
Nigel Goldsmith	CFO, Secretary & Executive Director	12yrs	UK£166.00k	0.042% £ 83.0k
Marybeth Thompson	Chief Operating Officer	6.8yrs	Nessun dato	Nessun dato
Gordon Baxter	Chief Scientific Officer	no data	Nessun dato	Nessun dato
Mark Poggi	Executive Vice President of Global Sales	less than a year	Nessun dato	Nessun dato
Eve Leconte	Chief People & Culture Officer	4.8yrs	Nessun dato	Nessun dato
Mike Harwood	Chief Product Officer	no data	Nessun dato	Nessun dato
Gregor Grant	Executive Vice President of Preclinical Solutions	no data	Nessun dato	Nessun dato
John Leveille	Executive Vice President of Clinical Trial Acceleration	less than a year	Nessun dato	1.79% £ 3.6m

4.8yrs

Durata media

Gestione esperta: Il team dirigenziale di INS è considerato esperto (durata media dell'incarico 4.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Phil Reason	CEO & Executive Director	no data	UK£300.00k	3.2% £ 6.4m
Nigel Goldsmith	CFO, Secretary & Executive Director	12yrs	UK£166.00k	0.042% £ 83.0k
Riaz Bandali	Independent Non-Executive Director	1.9yrs	UK£36.00k	Nessun dato
Michael McGoun	Non-Executive Director	no data	UK£40.00k	Nessun dato
David Gare	Non-Executive Chairman	no data	UK£65.00k	5.52% £ 11.0m
Mary Dolson	Independent Non-Executive Director	less than a year	Nessun dato	Nessun dato

1.9yrs

Durata media

62.5yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di INS non è considerato esperto (durata media del mandato 1.9 anni), il che suggerisce un nuovo consiglio.

Instem Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Less than half of directors are independent

Instem plc, Annual General Meeting, Jun 27, 2023

Instem plc Announces Board and Committee Appointments

CEO & Executive Director exercised options and sold UK£143k worth of stock

Less than half of directors are independent

Instem plc, Annual General Meeting, Jun 09, 2022

Recent updates

Instem Enables Clients to Leverage ICH S1B Weight of Evidence Guideline

ArchiMed SAS agreed completed the acquisition of Instem plc (AIM : INS) from group of sellers.

ArchiMed SAS agreed completed the acquisition of Instem plc (AIM : INS) from group of sellers.

Instem's Shares to Trading on AIM Expected to Be Cancelled on 21 November 2023

Here's Why We Think Instem (LON:INS) Might Deserve Your Attention Today

New minor risk - Earnings quality

ArchiMed SAS agreed to acquire Instem plc (AIM : INS) from group of sellers for approximately £190 million.

ArchiMed SAS agreed to acquire Instem plc (AIM : INS) from group of sellers for approximately £190 million.

An Intrinsic Calculation For Instem plc (LON:INS) Suggests It's 29% Undervalued

Less than half of directors are independent

Instem plc, Annual General Meeting, Jun 27, 2023

Ennov SA acquired Samarind Ltd from Instem plc (AIM:INS).

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Instem plc Announces Board and Committee Appointments

CEO & Executive Director exercised options and sold UK£143k worth of stock

Price target increased to UK£10.10

Less than half of directors are independent

Instem Unveils New Additions to Its Leading Computational Toxicology Software Suite

First half 2022 earnings released: EPS: UK£0.057 (vs UK£0.048 in 1H 2021)

Instem plc Announces Settlement of Historical Licence Dispute

Instem plc to Report First Half, 2022 Results on Sep 27, 2022

Instem plc, Annual General Meeting, Jun 09, 2022

European Medicines Agency Awards Research Grant to Instem

Instem plc Receives European Medicines Agency Research Grant

Full year 2021 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Instem plc to Report Fiscal Year 2021 Results on Apr 26, 2022

Investor sentiment deteriorated over the past week

CEO & Executive Director exercised options and sold UK£298k worth of stock

Instem plc Provides Revenue Guidance for the Year Ended 31 December 2021

Instem plc (LON:INS) Shares Could Be 45% Below Their Intrinsic Value Estimate

Instem plc Announces the Release of the Latest Edition of Its Leadscope Model Applier Computational Toxicology Software Solution

First half 2021 earnings released: EPS UK£0.048 (vs UK£0.095 in 1H 2020)

Instem plc's (LON:INS) Intrinsic Value Is Potentially 44% Above Its Share Price

Instem plc (AIM:INS) acquired PDS Pathology Data Systems Ltd. for CHF 14.2 million.

Instem plc (AIM:INS) acquired PDS Pathology Data Systems Ltd for CHF 14.2 million.

Full year 2020 earnings released: EPS UK£0.12 (vs UK£0.057 loss in FY 2019)

Instem plc (AIM:INS) acquired The Edge Software Consultancy Ltd. for £8.5 million.

Is Instem plc's (LON:INS) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

New 90-day high: UK£5.20

Shareholders Are Thrilled That The Instem (LON:INS) Share Price Increased 190%

New 90-day high: UK£5.08

Calculating The Intrinsic Value Of Instem plc (LON:INS)

Instem plc Provides New Business Update

Instem Launches in Silico Toxicology Service

New 90-day low: UK£4.40

First half earnings released

New 90-day high - UK£5.45

Instem plc has completed a Follow-on Equity Offering in the amount of £15.750002 million.

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media

Età media